Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milciclib plus Gemcitabine in KRAS-mutated NSCLC
NCT05651269Phase 2Unknown
- Sponsor
- Tiziana Life Sciences
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of milciclib in non-small cell lung cancer (NSCLC), sponsored by Tiziana Life Sciences. Status: unknown.
02
Drugs
milciclib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05651269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651269.